ArticleViruses2020
RNAemia Corresponds to Disease Severity and Antibody Response in Hospitalized COVID-19 Patients.
Article in Viruses, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 2 syntheses or guidelines pooled it, 68 citations in OpenAlex.
- Efficacy and safety of nitazoxanide in treating SARS-CoV-2 infection: a systematic review and meta-analysis of blinded, placebo-controlled, randomized clinical trials.European journal of clinical pharmacology · 2022Pooled it
- Quantitative assessment of SARS-CoV-2 RNAemia and outcome in patients with coronavirus disease 2019.Journal of medical virology · 2021Pooled it
- Convalescent or standard plasma versus standard of care in the treatment of COVID-19 patients with respiratory impairment: short and long-term effects. A three-arm randomized controlled clinical trial.BMC infectious diseases · 2022Trial
- Combined elevated C-reactive protein and detectable plasma RNA has predictive value for hospitalization during an outpatient COVID-19 convalescent plasma clinical trial.Journal of clinical virology plus · 2026Article
- Detectability of Pathogenic RNA Virus Families in Different Body Sites: A Scoping Review.Viruses · 2026Article
- Droplet Digital PCR or Real-Time PCR as a Method for Quantifying SARS-CoV-2 RNA in Plasma-Is There a Difference?Viruses · 2025Article
- Article
- Article
- COVID-19 Biomarkers at the Crossroad between Patient Stratification and Targeted Therapy: The Role of Validated and Proposed Parameters.International journal of molecular sciences · 2023Review
- Article
- Microbead-based extracorporeal immuno-affinity virus capture: a feasibility study to address the SARS-CoV-2 pandemic.Mikrochimica acta · 2023Article
- Diagnostic value and characteristic analysis of serum nucleocapsid antigen in COVID-19 patients.PeerJ · 2023Article
- Evaluation of the transmission of SARS-CoV-2 through breast milk: a case series.Frontiers in pediatrics · 2023Article
- Longitudinal Characterization of a Neutralizing and Total Antibody Response in Patients with Severe COVID-19 and Fatal Outcomes.Vaccines · 2022Article
- Usefulness of real-time RT-PCR to understand the kinetics of SARS-CoV-2 in blood: A prospective study.Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology · 2022Observational
- SARS-CoV-2 Virology.Infectious disease clinics of North America · 2022Review
- Association of high SARS-CoV-2 RNAemia with diabetes and mortality in critically ill COVID-19 patients.iScience · 2022Article
- Combined kinetic analysis of SARS-CoV-2 RNAemia, N-antigenemia and virus-specific antibodies in critically ill adult COVID-19 patients.Scientific reports · 2022Article
- Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults.Nature medicine · 2022Article
- Evaluation of two RT-PCR techniques for SARS-CoV-2 RNA detection in serum for microbiological diagnosis.Journal of virological methods · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) represents a global health emergency. To improve the understanding of the systemic component of SARS-CoV-2, we investigated if viral load dynamics in plasma and respiratory samples are associated with antibody response and severity of coronavirus disease 2019 (COVID-19). SARS-CoV-2 RNA was found in plasma samples from 14 (44%) out of 32 patients. RNAemia was detected in 5 out of 6 fatal cases. Peak IgG values were significantly lower in mild/moderate than in severe (0.6 (interquartile range, IQR, 0.4-3.2) vs. 11.8 (IQR, 9.9-13.0), adjusted
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.